Home » Newsletters » BioWorld

BioWorld

Jan. 11, 2001

View Archived Issues

Pharmos Starts Phase III Study Of Dexanabinol In Brain Injury

SciClone Begins Pivotal U.S. Trial Of Zadaxin In Hepatitis C Patients

Other News To Note

Clarification

Collateral, Berlex Plan Pivotal Angiogenic Gene Therapy Trial

Switching On Apaf-1, A Protein Inactivated In Tumors, To Revive Effectiveness Of Chemotherapy

Millennium Delivering To Bayer 'First Genomics-Derived' Target

Nexell Agrees To Sell Up To $25M In Shares To Acqua Wellington

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026